Abstract
Nuclear receptors for retinoic acid are important modulators of epidermal cell proliferation and terminal differentiation. Aberrant expression of retinoic acid receptors (RARs) and retinoid X receptors in the epidermis has been associated with altered differentiation capacity and tumor progression. In this study, we describe a human squamous cell carcinoma line, SCC 12F, which displays reduced RARγ expression and diminished responsiveness to retinoic acid. When compared with normal keratinocytes or other squamous cell carcinoma lines that display normal levels of RARγ, several measures of cellular response to retinoic acid are altered in SCC 12F cells, including inhibition of cornified envelope formation, reduction of involucrin mRNA expression, and transcriptional regulation of the involucrin gene. Normal patterns of ligand-dependent transcriptional response were restored upon co-transfection of an expression vector containing either RARα or RARγ. Our findings demonstrate that reduced expression of RAR may have direct functional consequences with regard to keratinocyte differentiation and that the defect may be alleviated by reintroduction of functional receptor.
Footnotes
-
Send reprint requests to: Dr. Laurie Hudson, Dept. of Molecular Pharmacology and Biological Chemistry, Searle 8–565, Northwestern University, 303 East Chicago Ave., Chicago, IL 60611.
-
This work was supported by American Cancer Society Grants BE-135 and JFRA-380 and in part by grant 0439 from the Smokeless Tobacco Research Council, Inc. R.I.M. is supported by National Institutes of Health training grant T32-ES07124–11.
- Abbreviations:
- RAR
- retinoic acid receptor
- RXR
- retinoid X receptor
- DME
- Dulbecco’s modified Eagle’s medium
- F12
- Ham’s F12 nutrient mixture
- SCC
- squamous cell carcinoma
- GAPDH
- glyceraldehyde-3-phosphate dehydrogenase
- TPA
- 12-O-tetradecanoylphorbol-13-acetate
- bp
- base pair(s)
- AP1
- activator protein 1
- Received July 29, 1996.
- Accepted December 6, 1996.
- The American Society for Pharmacology and Experimental Therapeutics
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|